Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Plaque psoriasis

Plaque psoriasis

Part of Psoriasis

16 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Plaque psoriasis

202 trials tracked for Plaque psoriasis: 109 in phase 3 or 4 and 44 with published results. The most-cited published study has 565 citations.

202Trials tracked
109Phase 3 & 4
0Recruiting
44With published results
Phase distribution
Phase 4 35 Phase 3 74 Phase 2 71 Phase 1 7 Other / NA 15
  1. Phase 3 A Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous Tildrakizumab (SCH 900222/MK-3222) in Participants With Moderate-to-Severe Chronic Plaque Psoriasis Followed by a Long-term Extension Study (MK-3222-011) Completed · 565 cited
  2. Phase 3 A Study to Evaluate the Efficacy and Safety of Subcutaneous MK-3222, Followed by an Optional Long-Term Safety Extension Study, in Participants With Moderate-to-Severe Chronic Plaque Psoriasis (MK-3222-010) Completed · 565 cited
  3. Phase 3 Tapinarof for the Treatment of Plaque Psoriasis in Adults (3002) Completed · 194 cited
  4. Phase 3 Tapinarof for the Treatment of Plaque Psoriasis in Adults (3001) Completed · 194 cited
  5. Phase 3 An Efficacy and Safety Study of Two Dose Levels of Certolizumab Pegol (CZP) in Subjects With Plaque Psoriasis (PSO) Completed · 157 cited
  6. Phase 3 A Study to Evaluate the Efficacy and Safety of Two Dose Levels of Certolizumab Pegol (CZP) in Subjects With Plaque Psoriasis (PSO) Completed · 156 cited
Show 44 more trials
  1. Phase 3 A Double Blind Study in Pediatric Subjects With Chronic Plaque Psoriasis, Studying Adalimumab vs. Methotrexate Completed · 153 cited
  2. Phase 3 Efficacy and Safety Study of Certolizumab Pegol (CZP) Versus Active Comparator and Placebo in Subjects With Plaque Psoriasis (PSO) Completed · 133 cited
  3. Phase 4 A Study of Ixekizumab (LY2439821) Compared to Guselkumab in Participants With Moderate-to-Severe Plaque Psoriasis Completed · 122 cited
  4. Phase 3 Twin Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis Completed · 116 cited
  5. Phase 3 Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis Completed · 116 cited
  6. Phase 3 LEO 90100 Aerosol Foam Compared to Calcipotriol Plus Betamethasone Dipropionate Gel in Subjects With Psoriasis Vulgaris Completed · 113 cited
  7. Phase 4 Study to Evaluate the Effect of Secukinumab Compared to Placebo on Aortic Vascular Inflammation in Subjects With Moderate to Severe Plaque Psoriasis Completed · 96 cited
  8. Phase 3 LEO 90100 Compared to Vehicle in Subjects With Psoriasis Vulgaris Completed · 96 cited
  9. Phase 3 Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis Completed · 76 cited
  10. Phase 3 A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis Completed · 66 cited
  11. Phase 3 A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis Completed · 66 cited
  12. Phase 3 A Study With a Initial Treatment Period Followed by a Randomized-withdrawal Period to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis Completed · 66 cited
  13. Phase 3 A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Placebo and an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis Completed · 64 cited
  14. Phase 3 Study of Efficacy and Safety of Secukinumab in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Completed · 51 cited
  15. Phase 3 Study of Ixekizumab (LY2439821) in Children 6 to Less Than 18 Years With Moderate-to-Severe Plaque Psoriasis Completed · 44 cited
  16. Phase 3 A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque Psoriasis Naive to Systemic Treatment Completed · 44 cited
  17. Phase 3 A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis Completed · 42 cited
  18. Phase 3 Evaluation of Ixekizumab Using Auto-Injector or Prefilled Syringe in Participants With Moderate to Severe Plaque Psoriasis Completed · 41 cited
  19. Phase 3 A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque Psoriasis Completed · 40 cited
  20. Phase 4 A Study to Evaluate Clear Skin Effect on Quality of Life in Patients With Plaque Psoriasis. Completed · 38 cited
  21. Phase 3 This Trial is a Randomised, Multicentre, Investigator-blind, Vehicle and Comparator-controlled, Parallel-group Trial With the Purpose of Evaluation Efficacy, Safety and Convenience of the MC2-01 Cream Completed · 28 cited
  22. Phase 3 A Study to Investigate ABP 654 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis Completed · 17 cited
  23. Phase 3 A Clinical Trial Evaluating Efficacy and Safety of MC2-01 Cream Completed · 13 cited
  24. Phase 3 A Phase 3B, Open-label, Single-arm Study of the Efficacy and Safety of Apremilast, in Subjects With Plaque Psoriasis That is Not Adequately Controlled by Topical Therapy Completed · 13 cited
  25. Phase 3 Long Term Extension Study of Tapinarof for Plaque Psoriasis in Adults (3003) Completed · 12 cited
  26. Phase 4 Pain Outcomes Following Intralesional Corticosteroid Injections Completed · 9 cited
  27. Phase 3 LEO 90100 Twice Weekly Maintenance Regimen for Psoriasis Vulgaris Completed · 9 cited
  28. Phase 4 Study to Evaluate the Efficacy of Etanercept Treatment in Adults Who Failed Therapy With Apremilast Completed · 7 cited
  29. Phase 3 A Study of Ixekizumab (LY2439821) in Chinese Participants With Moderate-to-Severe Plaque Psoriasis Completed · 7 cited
  30. Phase 3 A Study to Evaluate the Safe and Effective Use of the Prefilled Safety Syringe or the Auto-injector for the Subcutaneous Self-injection of Bimekizumab Solution by Subjects With Moderate to Severe Chronic Plaque Psoriasis (PSO) Completed · 5 cited
  31. Phase 3 A Study of the Safety and Efficacy of Risankizumab in Adult Participants With Plaque Psoriasis Who Have Had a Suboptimal Response to Secukinumab or Ixekizumab Completed · 4 cited
  32. Phase 3 Hulio Interchangeability to Humira®, Comparing Pharmacokinetics, Efficacy, Safety and Immunogenicity Completed · 3 cited
  33. Phase 4 Ammonium Lactate Lotion 12% (Lac-hydrin®) and Halobetasol Propionate Ointment 0.05% (Ultravate®) in the Treatment and Maintenance of Psoriasis Completed · 2 cited
  34. Phase 3 A Comparative Study Between ABP 501 and Humira® in Participants With Moderate to Severe Plaque Psoriasis Completed · 1 cited
  35. Phase 4 Study to Explore the Effect of Secukinumab, Compared to Placebo, on Fat Tissue and Skin in Plaque Psoriasis Patients Completed
  36. Phase 4 Study of the Efficacy of Early Intervention With Secukinumab 300 mg s.c. Compared to Narrow-band UVB in Patients With New-onset Moderate to Severe Plaque Psoriasis Completed
  37. Phase 3 A Comparison of 122-0551 Foam Versus Vehicle Foam in Subjects With Plaque Psoriasis (Study 310) Completed
  38. Phase 3 A Comparison of 122-0551 Foam Versus Vehicle Foam in Subjects With Plaque Psoriasis (Study 306) Completed
  39. Phase 4 Study to Assess the Immunogenicity and Safety of Etanercept Produced Using a Modified Process in Patients With Plaque Psoriasis Completed
  40. Phase 4 Plaque Psoriasis Study in Pediatric Subjects Completed
  41. Phase 4 PK and PD Study of Calcitriol 3 mcg/g Ointment in Pediatric Subjects With Plaque Psoriasis Completed
  42. Phase 4 Open-label Study of Subcutaneous Secukinumab to Evaluate Efficacy and Safety in Patients With Plaque Psoriasis Who Had Inadequate Response to Cyclosporine A Completed
  43. Phase 4 Patient Preference of Taclonex Ointment to Taclonex Scalp Suspension in Adult Subjects With Psoriasis Vulgaris Completed
  44. Phase 4 Apremilast 30mg Bid With Narrowband UVB in the Treatment of Plaque Psoriasis Completed

Showing the 50 most-cited and recently-updated of 202 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Plaque psoriasis: what the trials found

Several biologics demonstrate significant efficacy in treating plaque psoriasis. Bimekizumab achieved a PASI90 response rate of 94.0% and an IGA 0/1 response rate of 92.0% at week 16 1. Ixekizumab demonstrated high rates of PASI 90 (58.5%) and PASI 75 (22.9%) in a large-scale study, with significant superiority over the comparator in both metrics 7. Additionally, Ixekizumab showed an 86.0% PASI-75 response rate at week 12 in patients with no active psoriatic arthritis 13.

JNJ-77242113 demonstrated consistent improvements across multiple trials; notably, it achieved a PASI-75 of 58.1% to 78.6% and PASI-90 rates ranging from 25.6% to 59.5% at week 16 [3, 5]. Secukinumab showed significant PASI 90 results at week 52 (70 participants vs 32 in the comparator) 14, and was associated with high DLQI 0/1 response rates of approximately 61.7% to 74.7% at both weeks 16 and 52 9. Tildrakizumab showed sustained PASI scores through week 96 6.

Etanercept achieved a PASI-75 response of 41.6% by week 12, with PASI-50 rates reaching up to 74.0% during the observation period 11. Apremilast demonstrated significant improvements in nail psoriasis, including a mean 64.1% reduction in mNAPSI at week 36 and a 50.42% reduction in patient-reported nail pain by week 52 19.

Various topical and localized treatments were evaluated: DFD-01 (betamethasone dipropionate) spray resulted in reductions in Investigator's Global Assessment grade (-0.8) and body surface area involvement (-1.3) 21. Lac-Hydrin lotion combined with UItravate ointment showed significant improvements in physical global assessment and signs of psoriasis, atrophy, or telangiectasis 12.

Recent results — preliminary, needs further review

  • Total coumarin (TC) cream was evaluated for PASI 75 improvement (9% vs 1%) and DLQI scores 4.

For the clinician treating this condition

  • Bimekizumab, Ixekizumab, and JNJ-77242113 are established options with high PASI-90 and PASI-75 response rates.
  • Secukinumab provides consistent improvement in both clinical scores (PASI) and patient-reported quality of life (DLQI).
  • Apremilast is an established option for managing nail psoriasis, showing significant reduction in mNAPSI and reported pain.

AI synthesis of 11 cited trials, updated Jun 20, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Oral ME3183 shows higher PASI-75 response rates than placebo in moderate to severe plaque psoriasis trial
Dermatology RCT
Oral ME3183 shows higher PASI-75 response rates than placebo in moderate to severe plaque psoriasis trial Could a new pill help clear stubborn psoriasis skin plaques?
A 16-week randomized controlled trial in 132 patients with moderate to severe plaque psoriasis found higher proportions achieving ≥75% PASI …
A new oral pill helped over 60% of patients with moderate to severe psoriasis clear skin plaques significantly better than a placebo in a re…
Apr 1, 2026
Phase 2a study of bimekizumab in chronic plaque psoriasis reports pharmacokinetics and PASI change at Week 28
Dermatology Phase II
Phase 2a study of bimekizumab in chronic plaque psoriasis reports pharmacokinetics and PASI change at Week 28 Could a new psoriasis treatment work better by targeting two inflammation sources at once?
A Phase 2a, multicenter, randomized, subject- and investigator-blind study investigated the pharmacokinetics, pharmacodynamics, and safety o…
A new psoriasis drug targets two inflammation sources to see if it works better for thick, scaly skin patches in adults.
CT.gov Mar 30, 2026
Phase 3 trial compares bimekizumab to placebo and ustekinumab for moderate to severe plaque psoriasis
Rheumatology Phase III
Phase 3 trial compares bimekizumab to placebo and ustekinumab for moderate to severe plaque psoriasis Can a new psoriasis drug outperform an established treatment?
A phase 3 randomized controlled trial enrolled 567 adults with moderate to severe chronic plaque psoriasis to compare bimekizumab against pl…
A new psoriasis drug called bimekizumab is being tested against existing treatments in a major trial involving 567 adults to see if it helps…
CT.gov Mar 30, 2026
Phase 3 trial of bimekizumab versus placebo in 435 adults with moderate to severe plaque psoriasis
Dermatology Phase III
Phase 3 trial of bimekizumab versus placebo in 435 adults with moderate to severe plaque psoriasis Can a new drug help people with moderate to severe plaque psoriasis?
A phase 3 randomized controlled trial evaluated bimekizumab versus placebo in 435 adults with moderate to severe chronic plaque psoriasis.
A new drug tested in a large study aims to help clear skin for people with moderate to severe plaque psoriasis.
CT.gov Mar 30, 2026

Research across Psoriasis

Related studies from across the Psoriasis family.

Neural interactions and cellular components in psoriasis may offer new therapeutic targets for treatment
Dermatology Sys. Review
Neural interactions and cellular components in psoriasis may offer new therapeutic targets for treatment New Research Identifies Nervous System Links in Psoriasis Treatment
This systematic review examines the interactions between multiple cellular components and the nervous system in psoriasis. The review aims t…
New research explores how the nervous system interacts with skin cells in psoriasis to help identify new ways to treat the condition.
Frontiers Sep 10, 2026
Ustekinumab May Improve Inverse Psoriasis in Single Case Report
Dermatology Guideline
Ustekinumab May Improve Inverse Psoriasis in Single Case Report Ustekinumab Shows Promise for Treatment of Inverse Psoriasis
This is a single case report of a 32-year-old male with inverse psoriasis treated with four subcutaneous ustekinumab injections. Skin lesion…
A new case report shows how a specific medication, ustekinumab, significantly improved skin lesions and itching for a patient with inverse p…
Frontiers Sep 10, 2026
Vunakizumab may induce severe ulcerative colitis and hepatic enzyme elevation in patients with psoriatic arthritis
Allergy & Immunology Sys. Review
Vunakizumab may induce severe ulcerative colitis and hepatic enzyme elevation in patients with psoriatic arthritis Vunakizumab Linked to Severe Ulcerative Colitis in Single Case
This case report and literature review describes a single case of severe ulcerative colitis and hepatic enzyme elevation following vunakizum…
A single case report shows a patient developed severe ulcerative colitis and high liver enzymes after receiving vunakizumab injections.
Frontiers Sep 4, 2026
Older age, higher BMI, and comorbidities are associated with lower clearance rates in psoriasis patients
Dermatology Meta-analysis
Older age, higher BMI, and comorbidities are associated with lower clearance rates in psoriasis patients Factors Like Age and BMI Impact Psoriasis Treatment Success
This meta-analysis of 13,902 patients evaluates predictors of clinical response to biologic therapies in psoriasis. The analysis identifies …
New data shows that age, body mass index, and other health factors can influence how well patients with psoriasis respond to biologic therap…
Sep 1, 2026
IL-17 axis targeting shows substantial efficacy but faces cost and delivery hurdles
Drug Pipeline Sys. Review
IL-17 axis targeting shows substantial efficacy but faces cost and delivery hurdles IL-17 blockers show promise for autoimmune diseases
This systematic review examines IL-17 axis targeting with monoclonal antibodies and small-molecule inhibitors across psoriasis, lupus, perio…
New review finds IL-17-targeting drugs work well for psoriasis and other conditions, but cost and side effects remain hurdles.
Frontiers Aug 23, 2026
78 plasma proteins linked to psoriasis; 12 prioritized as potential drug targets
Genetics & Precision Medicine Meta-analysis
78 plasma proteins linked to psoriasis; 12 prioritized as potential drug targets 78 proteins linked to psoriasis may reveal new drug targets
This meta-analysis of genome-wide association studies (GWAS) identified 78 circulating proteins with genetically predicted associations with…
A large genetic study found 78 proteins tied to psoriasis, including 12 promising drug targets. This could lead to new treatments.
medRxiv Aug 22, 2026
Psoriasis patients with moderate to severe disease show higher prevalence of type 2 diabetes
Rheumatology Sys. Review
Psoriasis patients with moderate to severe disease show higher prevalence of type 2 diabetes Psoriasis patients face higher risk of type 2 diabetes
This narrative review explores the link between psoriasis and type 2 diabetes mellitus, highlighting shared inflammatory pathways and metabo…
People with psoriasis are more likely to develop type 2 diabetes because both conditions share common pathways of chronic inflammation.
Frontiers Aug 11, 2026
Chronic dermatologic conditions significantly impact psychological distress and health-related quality of life in pediatric patients
Pediatrics Meta-analysis
Chronic dermatologic conditions significantly impact psychological distress and health-related quality of life in pediatric patients Chronic skin conditions cause significant emotional distress in children
This systematic review of 41 studies examines the impact of chronic skin disorders on psychological outcomes and health-related quality of l…
Children with chronic skin conditions like psoriasis and eczema face high rates of anxiety, depression, and social struggles.
Frontiers Aug 5, 2026
GDF15 acts as a multi-node signaling hub in inflammatory skin diseases and systemic sclerosis
Neurology Sys. Review
GDF15 acts as a multi-node signaling hub in inflammatory skin diseases and systemic sclerosis Growth Factor GDF15 Linked to Skin Aging and Inflammation
This narrative review explores GDF15 as a signaling hub affecting melanocyte activity, fibroblast collagen synthesis, and the IL-23/Th17 axi…
A protein called GDF15 may play a key role in skin aging, pigmentation, and inflammatory conditions like psoriasis.
Frontiers Aug 2, 2026
Obesity is associated with lower PASI90, PASI75, and PASI100 responses in patients with psoriasis
Diabetes & Endocrinology Meta-analysis
Obesity is associated with lower PASI90, PASI75, and PASI100 responses in patients with psoriasis Obesity May Impact How Well Certain Psoriasis Drugs Work
This meta-analysis of 4200 patients found that obesity is associated with lower PASI90 (RR = 0.64), PASI75 (RR = 0.52), and PASI100 (RR = 0.…
New data suggests that patients with obesity may see lower response rates to certain biologic treatments for psoriasis.
Jul 22, 2026
Calcium signaling dysregulation drives keratinocyte defects and immune activation in psoriasis
Allergy & Immunology Sys. Review
Calcium signaling dysregulation drives keratinocyte defects and immune activation in psoriasis Calcium signaling problems may drive the cycle of psoriasis
This systematic review synthesizes evidence that impaired calcium sensing and SOCE dysfunction in keratinocytes, alongside persistently acti…
New research identifies how faulty calcium signals in skin cells and immune cells could be a key driver of psoriasis symptoms.
Frontiers Jul 15, 2026
Staphylococcal infections may mimic paradoxical psoriasis in patients receiving TNF-alpha inhibitors for systemic conditions
Allergy & Immunology Sys. Review
Staphylococcal infections may mimic paradoxical psoriasis in patients receiving TNF-alpha inhibitors for systemic conditions Skin infections can mimic psoriasis during certain medical treatments
This case report series describes 6 patients treated with TNF-alpha antagonists who developed skin lesions initially misdiagnosed as paradox…
Some patients treated for skin conditions may actually have a bacterial infection that looks like a flare-up of their original condition.
Frontiers Jun 9, 2026

Questions about Plaque psoriasis

How does bimekizumab compare to placebo for treating moderate to severe chronic plaque psoriasis?

Bimekizumab is significantly more effective than placebo for clearing skin in moderate to severe chronic plaque psoriasis, with Phase 3 trials showing high response rates at week 16.

Full answer →
Can Stelara be used to treat plaque psoriasis in pediatric patients 6 years and older?

Yes, Stelara (ustekinumab) is FDA-approved for treating moderate to severe plaque psoriasis in pediatric patients 6 years and older.

Full answer →
Is Cosentyx approved for adults with moderate to severe plaque psoriasis?

Yes, Cosentyx (secukinumab) is FDA-approved for adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

Full answer →
Are biologic drugs better than placebo for treating plaque psoriasis in children?

Yes, biologic drugs are significantly more effective than placebo for treating moderate to severe plaque psoriasis in children aged 6 years and older, based on multiple clinical trials and meta-analyses.

Full answer →